3H-imipramine and3H-cyano-imipramine binding in rat brain tissue: Effect of long-term antidepressant administration

Summary

3H-imipramine and3H-cyano-imipramine binding was determined in brain homogenates of rats which had been treated for 21 days with imipramine or desimipramine. When compared to control animals, long-term administration of these antidepressants did not induce any alteration in the maximal number of3H-imipramine or3H-cyano-imipramine binding sites. However, a transient increase in the apparent dissociation constant was observed. Such findings are discussed in respect to previous studies, which have been highly contraversial.

This is a preview of subscription content, log in to check access.

References

  1. Abel M. S., Meyerson, L. R., Clody, D. E., Wennogle, L. P.: Chronic electroconvulsive shock differentially affects brain and platelet3H-imipramine recognition sites. Abstract 210.2, 13th Annual Meeting of the American Society for Neurosciences, Boston (1983).

  2. Arbilla, S., Briley, M., Cathala, F., Langer, S. Z., Porin, C., Raisman, R.: Parallel changes in3H-imipramine binding sites in cat brain and platelets following chronic treatment with imipramine. Br. J. Pharmacol.72, 154p (1980).

    Google Scholar 

  3. Asarch, K. B., Shih, J. C., Kukcar, A.: Decreased3H-imipramine binding in depressed males and females. Commun. in Psychopharmacol.4, 425–432 (1980).

    Google Scholar 

  4. Banerjee, S. P., Kung, L. S., Riggi, S. J., Chanda, S. K.: Development of betaadrenergic receptor subsensitivity by antidepressants. Nature268, 455–456 (1977).

    PubMed  Google Scholar 

  5. Berrettini, W. H., Nurnberger, J. I., Post, R. M., Gershon, E. S.: Platelet3H-imipramine binding in euthymic bipolar patients. Psychiatry Res.7, 215–219 (1982).

    PubMed  Google Scholar 

  6. Borbe, H., Zube, I.: The detection of specific3H-imipramine binding sites in bovine retina. Brain Res.264, 178–180 (1983).

    PubMed  Google Scholar 

  7. Briley, M. S., Raisman, R., Langer, S. Z.: Human platelets possess high affinity binding sites for3H-imipramine. Eur. J. Pharmacol.58, 347–348 (1979).

    PubMed  Google Scholar 

  8. Briley, M. S., Fillion, G., Beaudoin, D., Fillion, M., Langer, S. Z.:3H-imipramine binding in neuronal and glial fractions of horse striatum. Eur. J. Pharmacol.64, 191–194 (1980).

    PubMed  Google Scholar 

  9. Briley, M. S., Langer, S. Z., Raisman, R., Sechter, D., Zarifian, E.: Tritiated imipramine binding sites are decreased in platelets of untreated depressed patients. Science209, 303–305 (1980).

    PubMed  Google Scholar 

  10. Briley, M. S., Raisman, R., Arbilla, S., Casadamont, M., Langer, S. Z.: Concomitant decrease in3H-imipramine binding in cat brain and platelets after chronic treatment with imipramine. Eur. J. Pharmacol.81, 309–314 (1982).

    PubMed  Google Scholar 

  11. Brunello, N., Chuang, D. M., Costa, E.: Different synaptic localization of mianserin and imipramine binding sites. Science215, 1112–1115 (1982).

    PubMed  Google Scholar 

  12. Burkard, W. P.: Specific binding sites in rat brain for a new and potent inhibitor of 5-hydroxytryptamine uptake: Ro 11-2465. Eur. J. Pharmacol.61, 409–410 (1980).

    PubMed  Google Scholar 

  13. Driscoll, P., Bättig, K.: Behavioral and physiological correlates of psychogenetic selection (RHA/Verh vs RLA/Verh rats). In: L'animal de laboratoire au service de l'homme. Collect. Fond. Mérieux, Lyon, 1979.

  14. Dumbrille-Ross, A., Tang, S. W.: Binding of3H-Ro 11-2465. Possible identification of a subclass of3H-imipramine binding sites. Molec. Pharmacol.23, 607–613 (1983).

    Google Scholar 

  15. Engel, G., Hoyer, D., Berthold, R., Wagner, H.: (+)(125Iodo)cyanopindolol, a new ligand for beta-adrenoceptors: Identification and quantification of subclasses of beta-adrenoceptors in guinea pig. Naunyn-Schmiedeberg's Arch. Pharmacol.317, 277–285 (1981).

    Google Scholar 

  16. Friedl, W., Propping, P., Weck, B.:3H-imipramine binding in platelets: influence of varying proportions of intact platelets in membrane preparations on binding. Psychopharmacology80, 96–99 (1983).

    PubMed  Google Scholar 

  17. Kinnier, W. J., Chuang, D., Costa, E.: Down regulation of dihydroalprenolol and imipramine binding sites in brain of rats repeatedly treated with imipramine. Eur. J. Pharmacol.67, 289–294 (1980).

    PubMed  Google Scholar 

  18. Langer, S. Z., Javoy-Agid, F., Raisman, R., Briley, M., Agid, Y.: Distribution of specific high-affinity binding sites for3H-imipramine in human brain. J. Neurochem.37, 267–271 (1981).

    PubMed  Google Scholar 

  19. Langer, S. Z., Zarifian, E., Briley, M., Raisman, R., Sechter, D.: High affinity H-imipramine binding: A new biological marker in depression. Pharmacopsychiatria15, 4–10 (1982).

    PubMed  Google Scholar 

  20. Lee, C., Javitch, J. A., Snyder, S. H.: Recognition sites for norepinephrine uptake: regulation by neurotransmitter. Science220, 626–629 (1983).

    PubMed  Google Scholar 

  21. Luine, V. N., Frankfurt, M., Rainbow, T. C., Biegon, A., Azmitia, E.: Intrahypothalamic 5, 7-dihydroxytryptamine facilitates feminine sexual behavior and decreases3H-imipramine binding and 5-HT uptake. Brain Res.264, 344–348 (1983).

    PubMed  Google Scholar 

  22. Mellerup, E. T., Plenge, P., Rosenberg, R.:3H-imipramine binding sites in platelets from psychiatric patients. Psychiatry Res.7, 221–227 (1982).

    PubMed  Google Scholar 

  23. Mogilnicka, E., Arbilla, S., Depoortere, H., Langer, S. Z.: Rapid eye movement sleep deprivation decreases the density of3H-dihydroalprenolol and3H-imipramine binding sites in the rat cerebral cortex. Eur. J. Pharmacol.65, 289–292 (1980).

    PubMed  Google Scholar 

  24. Paul, S. M., Rehavi, M., Skolnick, P., Ballenger, C., Goodwin, K.: Depressed patients have decreased binding of tritiated imipramine to platelet serotonin “transporter”. Arch. Gen. Psychiatry38, 1315–1317 (1981).

    PubMed  Google Scholar 

  25. Perry, E. K., Marshall, E. F., Blessed, G., Tomlinson, B. E., Perry, R. H.: Decreased imipramine binding in the brains of patients with depressive illness. Brit. J. Psychiatry142, 188–192 (1983).

    Google Scholar 

  26. Plenge, P., Mellerup, E. T.:3H-imipramine high-affinity binding sites in rat brain. Effects of imipramine and lithium. Psychopharmacology77, 94–97 (1982).

    PubMed  Google Scholar 

  27. Racagni, G., Mocchetti, I., Calderini, G., Battistella, A., Brunello, N.: Temporal sequence of changes in central noradrenergic system of rat after prolonged antidepressant treatment: receptor desensitization and neurotransmitter interactions. Neuropharmacology22, 415–424 (1983).

    PubMed  Google Scholar 

  28. Raisman, R., Briley, M. S., Langer, S. Z.: Specific tricyclic antidepressant binding sites in rat brain characterized by high-affinity3H-imipramine binding. Eur. J. Pharmacol.61, 373–380 (1980).

    PubMed  Google Scholar 

  29. Schaffner, W., Weissmann, C.: A rapid, sensitive and specific method for the determination of protein in dilute solutions. Analytical Biochemistry56, 502–514 (1973).

    PubMed  Google Scholar 

  30. Wan, D., Peck, E. J., Ho, B. T., Schoolar, J. C.: The residual effect of chronic neuroleptic treatment on the neuroleptic binding assay in rats. Life Sci.32, 1255–1262 (1983).

    PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Gentsch, C., Lichtsteiner, M. & Feer, H. 3H-imipramine and3H-cyano-imipramine binding in rat brain tissue: Effect of long-term antidepressant administration. J. Neural Transmission 59, 257–264 (1984). https://doi.org/10.1007/BF01255595

Download citation

Keywords

  • Public Health
  • Binding Site
  • Brain Tissue
  • Dissociation Constant
  • Imipramine